Literature DB >> 19887424

Adverse selection in the Medicare prescription drug program.

Gerald F Riley1, Jesse M Levy, Melissa A Montgomery.   

Abstract

The Medicare Part D drug benefit created choices for beneficiaries among many prescription drug plans with varying levels of coverage. As a result, Medicare enrollees with high prescription drug costs have strong incentives to enroll in Part D, especially in plans with more comprehensive coverage. To measure this potential problem of "adverse selection," which could threaten plans' finances, we compared baseline characteristics among groups of beneficiaries with various drug coverage arrangements in 2006. We found some significant differences. For example, enrollees in stand-alone prescription drug plans, especially in plans offering benefits in the coverage gap, or "doughnut hole," had higher baseline drug costs and worse health than enrollees in Medicare Advantage prescription drug plans. Although risk-adjusted payments and other measures have been put in place to account for selection, these patterns could adversely affect future Medicare costs and should be watched carefully.

Mesh:

Year:  2009        PMID: 19887424     DOI: 10.1377/hlthaff.28.6.1826

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  7 in total

1.  Using medicare data for comparative effectiveness research: opportunities and challenges.

Authors:  Vicki Fung; Richard J Brand; Joseph P Newhouse; John Hsu
Journal:  Am J Manag Care       Date:  2011       Impact factor: 2.229

2.  Impact of Concurrent Medication Use on Pancreatic Cancer Survival-SEER-Medicare Analysis.

Authors:  Muhammad S Beg; Arjun Gupta; David Sher; Sadia Ali; Saad Khan; Ang Gao; Tyler Stewart; Chul Ahn; Jarett Berry; Eric M Mortensen
Journal:  Am J Clin Oncol       Date:  2018-08       Impact factor: 2.339

3.  Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D.

Authors:  Gerald F Riley; Joan L Warren; Linda C Harlan; Steven A Blackwell
Journal:  Medicare Medicaid Res Rev       Date:  2011-12-13

4.  How does drug treatment for diabetes compare between Medicare Advantage prescription drug plans (MAPDs) and stand-alone prescription drug plans (PDPs)?

Authors:  Mujde Z Erten; Bruce Stuart; Amy J Davidoff; J Samantha Shoemaker; Lynda Bryant-Comstock; Rahul Shenolikar
Journal:  Health Serv Res       Date:  2012-12-03       Impact factor: 3.402

5.  Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States.

Authors:  Kenneth G Saag; Penny E Mohr; Laura Esmail; Amy S Mudano; Nicole Wright; Timothy Beukelman; Jeffrey R Curtis; Gary Cutter; Elizabeth Delzell; Lisa C Gary; T Michael Harrington; Swapna Karkare; Meredith L Kilgore; Cora Elizabeth Lewis; Rachael Moloney; Ana Oliveira; Jasvinder A Singh; Amy Warriner; Jie Zhang; Marc Berger; Steven R Cummings; Wilson Pace; Daniel H Solomon; Robert Wallace; Sean R Tunis
Journal:  Contemp Clin Trials       Date:  2012-07-05       Impact factor: 2.226

6.  Trends in outpatient antibiotic use and prescribing practice among US older adults, 2011-15: observational study.

Authors:  Scott W Olesen; Michael L Barnett; Derek R MacFadden; Marc Lipsitch; Yonatan H Grad
Journal:  BMJ       Date:  2018-07-27

7.  How can the regulator show evidence of (no) risk selection in health insurance markets? Conceptual framework and empirical evidence.

Authors:  Wynand P M M van de Ven; René C J A van Vliet; Richard C van Kleef
Journal:  Eur J Health Econ       Date:  2016-02-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.